22
Jan
2026
GSK Scoops Up RAPT, Genentech Bets on NC, & Relief for American Science
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Jan
2026
Helping People Lose Weight and Live Healthy: Ron Renaud on The Long Run
Ron Renaud is today’s guest on The Long Run. He is the CEO of Waltham, Mass.-based Kailera Therapeutics. Kailera is pursuing what could be the biggest opportunity in pharmaceutical industry history. It’s developing a portfolio of GLP-1-based drugs for obesity. Drugs in this category have been around a long time for treatment of Type 2 diabetes, but over the last... Read More